The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
|Videos|March 14, 2011
Dr. Siegel Discusses the New John Theurer Cancer Center
Author(s)David S. Siegel, MD, PhD
David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.
Advertisement
David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center. Before the construction of the new building, cancer treatment services were provided as part of the Hackensack University Medical Center.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5